Compliance and persistence with osteoporosis therapies

被引：28

作者：

Silverman S.L. ^{[1
]}

Gold D.T. ^{[1
]}

机构：

[1] University of California, Los Angeles/Cedars-Sinai, Beverly Hills, CA 90211

来源：

Current Rheumatology Reports | 2008年 / 10卷 / 2期

关键词：

Osteoporosis; Bisphosphonates; Alendronate; Zoledronic Acid; Risedronate;

D O I：

10.1007/s11926-008-0021-x

中图分类号：

学科分类号：

摘要：

The US Food and Drug Administration has approved a diverse group of effective osteoporosis therapies. However, these therapies obviously only work when patients with osteoporosis take them. Data from retrospective observational databases have shown poor compliance and persistence with all osteoporosis drugs, particularly oral bisphosphonate therapy. Patients on weekly therapies are more compliant and persistent than those on daily dosing. Data have also shown decreased fracture risk, decreased health care utilization, and lower costs in compliant and persistent patients. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：118 / 122

页数：4

共 50 条

[1] Improving compliance and persistence with drug therapies for osteoporosis
不详
CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S151 - S151
[2] Comparing the Efficacies of Bisphosphonates' Therapies for Osteoporosis Persistence and Compliance: A Systematic Review
Almohaileb, Faisal I.
Rasheed, Zafar
CURRENT MOLECULAR MEDICINE, 2022, 22 (03) : 274 - 284
[3] Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink
J. Morley
A. Moayyeri
L. Ali
A. Taylor
M. Feudjo-Tepie
L. Hamilton
J. Bayly
Osteoporosis International, 2020, 31 : 533 - 545
[4] Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink
Morley, J.
Moayyeri, A.
Ali, L.
Taylor, A.
Feudjo-Tepie, M.
Hamilton, L.
Bayly, J.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (03) : 533 - 545
[5] Improving compliance and persistence with bisphosphonate therapy for osteoporosis
Emkey, RD
Ettinger, M
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (04): : 18S - 24S
[6] A systematic review of persistence and compliance with bisphosphonates for osteoporosis
Cramer, J. A.
Gold, D. T.
Silverman, S. L.
Lewiecki, E. M.
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (08) : 1023 - 1031
[7] Understanding Patient Compliance and Persistence with Osteoporosis Therapy
Gold, Deborah T.
DRUGS & AGING, 2011, 28 (04) : 249 - 255
[8] A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer
D. T. Gold
S. L. Silverman
E. M. Lewiecki
Osteoporosis International, 2007, 18 : 1023 - 1031
[9] Understanding Patient Compliance and Persistence with Osteoporosis Therapy
Deborah T. Gold
Drugs & Aging, 2011, 28 : 249 - 255
[10] Compliance with drug therapies for the treatment and prevention of osteoporosis
McCombs, JS
Thiebaud, P
McLaughlin-Miley, C
Shi, JH
MATURITAS, 2004, 48 (03) : 271 - 287

← 1 2 3 4 5 →